PRKN and breast carcinoma: Furthermore, Shiam-Peng (2010) demonstrated that PARK2 contributes to cell cycle arrest and growth inhibition by specifically upregulating CDK6 mRNA levels in MCF7 breast cancer cells (Tay et al., 2010).